Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4079-4084

  Pfister, Christian ^a   Moore, Lynne ^a   Allard, Pierre ^a   Larue, Hélène ^a   Lacombe, Louis ^a   Têtu, Bernard ^a   Meyer, François ^a   Fradet, Yves ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ARTICLE; BLADDER CARCINOGENESIS; BLADDER TUMOR; CANCER SURVIVAL; CELL CYCLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; PAPILLOMA; PRIORITY JOURNAL; TUMOR RECURRENCE;

AGED; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0033385056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Koch, M., Hill, G. B., and McPhee, M. S. Factors affecting recurrence rates in superficial bladder cancer. J. Natl. Inst., 76: 1025-1029, 1986.
2. Kurth, K. H., Denis, L., Bouffioux, C., Sylvester, R., Debruyne, F. M. J., Pavone-Macaluso, M., and Oosterlinck, W. Factors affecting recurrence and progression in superficial bladder tumors. Eur. J. Cancer, 31: 1840-1846, 1995.
3. Malmstrom, P. U., Busch, C., and Norlen, B. J. Recurrence, progression and survival in bladder cancer. J. Urol. Nephrol., 21: 185-195, 1986.
4. Kiemeney, L. A. L., Witjes, J. A., Heijbroek, R. P., Verbeek, A. L. M., and Debruyne, F. M. J. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol., 150: 60-64, 1993.
5. Parmar, M. K. B., Freedman, L. S., Hargreave, T. B., and Tolley, D. A. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J. Urol., 142: 284-288, 1989.
6. Reading, J., Hall, R. R., and Parmar, M. K. B. The application of a prognostic factor analysis for Ta-T1 bladder cancer in routine urological practice. Br. J. Urol., 75: 604-607, 1995.
7. Allard, P., Bernard, P., Fradet, Y., and Têtu, B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br. J. Urol., 81: 692-698, 1998.
8. Cordon-Cardo, C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol., 147; 545-560, 1995.
9. Sarkis, A., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker of disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
10. Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder tumors. Am. J. Pathol., 143: 1389-1397, 1993.
11. Cote, R. J., and Chatterjee, S. J. Molecular determinants of outcome in bladder cancer. Cancer (Phila.) J., 5: 4-15, 1999.
12. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-MDM2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
13. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., and Cordon-Cardo, C. Altered patterns of MDM2 and p53 expression in human bladder cancer. J. Natl. Cancer Inst., 86: 1325-1330, 1994.
14. Schmitz-Dräger, B. J., Kushima, M., Goebell, P., Jax, T. W., Gerharz, C. D., Bültel, H., Schulz, W. A., Ebert, T., and Ackermann, R. p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol., 32: 487-493, 1997.
15. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., and Cote, R. J. Effect of p21/WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90: 1072-1079, 1998.
16. Okamura, K., Miyake, K., Koshikawa, T., and Asai, J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J. Urol., 144: 875-878, 1990.
17. Stravropoulos, N. E., loackim-Velogianni, E., Hastazeris, K., Kitsiou, E., Stefanaki, S., and Agnantis, N. Growth fractions in bladder cancer grade, category and recurrence rate of superficial lesions. Br. J. Urol., 72: 736-739, 1993.
18. Epstein, J. I., Amin, M. B., Reuter, V. R., Mostofi, F. K., and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology Consensus: classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol., 22: 1435-1448, 1998.
19. Larue, H., Allard, P., Simoneau, M., Normand, C., Pfister, C., Moore, L., Meyer, F., Têtu, B., and Fradet, Y. p53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis (Lond.), in press.
20. Reznikoff, C. A., Belair, C. D., Yeager, T. R., Savelieva, E., Blelloch, R. H., Puthenveettil, J. A., and Cuthill, S. Amolecular genetic model of human bladder cancer pathogenesis. Semin. Oncol., 23: 571-584, 1996.
21. Keegan, P. E., Lunec, J., and Neal, D. E. Review: p53 and p53-regulated genes in bladder cancer. Br. J. Urol., 82: 710-720, 1998.
22. Lane, D. P., and Hall, P. A. MDM2: arbiter of p53's destruction. Trends Biochem. Sci., 22: 372-374, 1997.
23. Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X., and Ronai, Z. MDM2 association with p53 targets its ubiquitination. Oncogene, 12: 2543-2547, 1998.
24. Momand, J., and Zambetti, G. P. MDM2: big brother of p53. J. Cell. Biochem., 64: 343-352, 1997.
25. Ohkoudou, M., Sawa, H., Hara, M., Saruta, K., Aiso, T., Ohki, R., Yamamoto, H., Maemura, E., Shiina, Y., Fujii, M., and Saito, I. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. J. Neurooncol., 38: 41-49, 1998.
26. Gerdes, J., Schwab, U., Lemke, H., and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13-20, 1983.
27. Tsuji, M., Kojima, K., Murakami, Y., Kanayama, H., and Kagawa, S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br. J. Urol., 79: 367-372, 1997.
28. Okamura, K., Miyake, K., Koshikawa, T., and Asai, J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J. Urol., 144: 875-878, 1990.
29. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by an independent pathway. Cancer Res., 54: 3391-3395, 1994.
30. Fredersdorf, S., Milne, A. W., Hall, P. A., and Lu, X. Characterization of a panel of novel anti-p21/WAF1/CIP1 monoclonal antibodies and immunochemical analysis of p21 expression in normal human tissues. Am. J. Pathol., 148: 825-835, 1996.
31. Mateo, M. S., Saez, A. I., Sanchez-Beato, M., Garcia, P., Sanchez-Verde, L., Martinez, J. C., Orradre, J. L., and Piris, M. A. Expression of p21/WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki-67 and p53. J. Clin. Pathol., 50: 645-653, 1997.
32. Stefanaki, K., Tzardi, M., Kouvidou, C., Chaniotis, V., Bolioti, M., Vlychou, M., Zois, M., Kakolyris, S., Delides, G., Rontogianni, D., Georgoulias, V., and Kanavaros, P. Expression of p53, p21, MDM2, Rb, Bax and Ki-67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res., 18: 2403-2408, 1998.
33. Allard, P., Fradet, Y., Têtu, B., Bernard, P., and the Quebec Urology Research Group. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin. Cancer Res., 1: 1195-1202, 1995.
34. Rao, J. Y., Hemstreet, G. P., Hurst, R. E., Bonner, R. A., Jones, P. L., Min. K. W., and Fradet, Y. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci. USA, 90: 8287-8291, 1993.
35. Lee, E., Schwaibold, H., Fradet, Y., Huland, E., and Huland, H. Tumor associated antigens in normal mucosa patients with superficial transitional-cell carcinoma of the bladder. J. Urol., 157: 1070-1073, 1997.